长循环的脂质体编码提供安二B和酸,用于皮肤莱什曼病治疗
Thais T Santos1,2, Eduardo B Lages3, Tiago N Q Ricotta3
1Institute of Biological Sciences, Federal University of Minas Gerais (UFMG), 31270-901 Belo Horizonte, Brazil.
ACS omega
|October 27, 2025
概括
一种新型的脂质体配方 (LAmB-RA) 联合封装了安福特素B和视网酸,可用于治疗皮肤莱什曼病. 这种增强的药物输送系统在临床前模型中证明了改善的药理动力学和显著减少寄生虫负担.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药物输送系统 药物输送系统
- 免疫学 免疫学 免疫学
背景情况:
- 莱什曼病是一种被忽视的热带疾病,治疗选择有限,特别是皮肤莱什曼病 (CL).
- 像AmBisome这样的常规安福特里辛B配方在CL和免疫受损患者中具有有效性限制.
- 网红素酸 (RA) 可以充当免疫调节剂,有可能提高治疗结果.
研究的目的:
- 评估一种新的PEGylated脂质体配方 (LAmB-RA),用于皮肤莱什曼病 (CL) 治疗,该配方同时封装氨基氨酸B (AmB) 和视网酸 (RA).
- 评估LAmB-RA的物理化学性质,药理动力学,体内疗效和免疫调节作用.
主要方法:
- 对LAmB-RA脂质体的表征 (大小,多分散性,封装效率).
- 分析AmB聚合状态和血液溶解活性.
- 在小鼠中的药理动力学研究比较LAmB-RA与AmBisome.
- 在Leishmania major和Leishmania amazonensis感染的小鼠模型中的体内疗效评估.
- 在细胞中评估免疫反应 (IFN-γ/IL-10比率).
主要成果:
- 对于AMB和RA来说,LAmB-RA表现出有利的物理化学特性,具有高的封装效率.
- 与AmBisome相比,LAmB-RA显示出降低的血液溶解活性和优越的药物动力学特征 (更高的Cmax,长时间暴露).
- 在L. major感染的小鼠中观察到病变大小和寄生虫负担的显著减少 (高达99%).
- 在L. amazonensis感染的小鼠中,明显抑制了病变进展,并显著减少了脏寄生虫负荷 (60%).
- LAmB-RA促进了Th1歪曲的免疫反应,由增加的IFN-γ/IL-10比率表明.
结论:
- 对于皮肤雷什曼病来说,LAmB-RA是一个有前途的治疗策略.
- 该配方将长时间的药物循环与增强的疗效和免疫调节性质相结合.
- 需要进一步的研究,以探索其在莱什曼病治疗中的临床潜力.
更多相关视频
12:22A Parasite Rescue and Transformation Assay for Antileishmanial Screening Against Intracellular Leishmania donovani Amastigotes in THP1 Human Acute Monocytic Leukemia Cell Line
Published on: December 30, 2012
22.9K
08:48Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation
Published on: January 26, 2016
12.3K
相关概念视频
01:30Leishmaniasis
Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...